NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board
NeOnc Technologies (NTHI), a clinical-stage biopharmaceutical company focused on CNS cancer therapies, has appointed Dr. Henry S. Friedman to its scientific advisory board. Dr. Friedman, a distinguished neuro-oncologist from Duke University's Preston Robert Tisch Brain Tumor Center, brings extensive expertise with over 500 peer-reviewed publications.
As a deputy director at the Brain Tumor Center and holder of the James B. Powell, Jr. Distinguished Professorship, Dr. Friedman's appointment comes at a crucial time as NeOnc prepares to publish data from its NEO100™ and NEO212™ clinical programs. His expertise will be instrumental in reviewing and validating these upcoming results, particularly in the areas of glioblastoma and other brain cancers.
NeOnc Technologies (NTHI), una società biofarmaceutica in fase clinica focalizzata sulle terapie per il cancro al sistema nervoso centrale, ha nominato il Dr. Henry S. Friedman nel suo consiglio consultivo scientifico. Il Dr. Friedman, distinto neuro-oncologo del Preston Robert Tisch Brain Tumor Center della Duke University, porta una vasta esperienza con oltre 500 pubblicazioni peer-reviewed.
In qualità di deputy director presso Brain Tumor Center e titolare della James B. Powell, Jr. Distinguished Professorship, la nomina del Dr. Friedman arriva in un momento cruciale mentre NeOnc si prepara a pubblicare i dati dei suoi programmi clinici NEO100™ e NEO212™. La sua esperienza sarà essenziale nella revisione e validazione di questi prossimi risultati, in particolare nelle aree di glioblastoma e altri tumori cerebrali.
NeOnc Technologies (NTHI), una empresa biofarmacéutica en etapa clínica centrada en terapias para el cáncer del sistema nervioso central, ha nombrado al Dr. Henry S. Friedman en su consejo asesor científico. El Dr. Friedman, destacado neuro-oncólogo del Preston Robert Tisch Brain Tumor Center de la Universidad Duke, aporta una amplia experiencia con más de 500 publicaciones revisadas por pares.
Como subdirector del Brain Tumor Center y titular de la Cátedra Distinguished James B. Powell, Jr., la designación del Dr. Friedman llega en un momento crucial mientras NeOnc se prepara para publicar datos de sus programas clínicos NEO100™ y NEO212™. Su experiencia será fundamental para revisar y validar estos próximos resultados, especialmente en las áreas de glioblastoma y otros cánceres del cerebro.
NeOnc Technologies (NTHI)는 중추 신경계(CNS) 암 치료에 중점을 둔 임상단계 생물의약 회사로, 헨리 S. 프리드먼 박사를 과학자문위원회로 임명했습니다. 프리드먼 박사는 듀크 대학교 프레스턴 로버트 티시 뇌종양센터의 저명한 신경종양학자로서 500편이 넘는 동료심사(Peer-Reviewed) 논문을 보유한 폭넓은 전문 지식을 제공합니다.
뇌종양센터의 부소장으로서 및 제임스 B. 파월 주니어 석좌교수의 재직자격을 가진 프리드먼 박사의 임명은 NeOnc가 임상 프로그램 NEO100™ 및 NEO212™의 데이터를 공개하려는 중요한 시점에 이뤄졌습니다. 그의 전문성은 이러한 향후 결과를 검토하고 검증하는 데 있어 특히 글리오블라스토마 및 기타 뇌암 분야에서 중요한 역할을 할 것입니다.
NeOnc Technologies (NTHI), une société biopharmaceutique en phase clinique axée sur les thérapies du cancer du système nerveux central, a nommé le Dr Henry S. Friedman à son conseil consultatif scientifique. Le Dr Friedman, neuro-oncologue distingué du Preston Robert Tisch Brain Tumor Center de l'Université Duke, apporte une expertise considérable avec plus de 500 publications évaluées par les pairs.
En tant que directeur adjoint du Brain Tumor Center et titulaire de la chaire Distinguished James B. Powell, Jr., la nomination du Dr Friedman intervient à un moment crucial alors que NeOnc se prépare à publier les données de ses programmes cliniques NEO100™ et NEO212™. Son expertise sera déterminante pour examiner et valider ces résultats à venir, en particulier dans les domaines du glioblastome et d'autres cancers cérébraux.
NeOnc Technologies (NTHI), ein klinisch erforschendes Biopharmaunternehmen, das sich auf Therapien gegen ZNS-Krebs konzentriert, hat Dr. Henry S. Friedman in seinen wissenschaftlichen Beirat berufen. Dr. Friedman, ein angesehener Neuro-Onkologe vom Preston Robert Tisch Brain Tumor Center der Duke University, bringt umfassende Expertise mit über 500 begutachteten Publikationen.
Als stellvertretender Direktor des Brain Tumor Center und Inhaber der James B. Powell, Jr. Distinguished Professorship erfolgt die Berufung von Dr. Friedman zu einem entscheidenden Zeitpunkt, da NeOnc beginnt, Daten aus seinen klinischen Programmen NEO100™ und NEO212™ zu veröffentlichen. Seine Expertise wird bei der Überprüfung und Validierung dieser kommenden Ergebnisse, insbesondere in den Bereichen Glioblastom und andere Gehirntumore, von entscheidender Bedeutung sein.
NeOnc Technologies (NTHI)، شركة أدوية حيوية في مرحلة سريرية تركز على علاجات سرطان الجهاز العصبي المركزي، قد عينت الدكتور هنري S. فريدمان في مجلسها الاستشاري العلمي. الدكتور فريدمان، أخصائي أمراض أورام الأعصاب من مركز كليّة Tisch لأورام الدماغ بجامعة دوك، يجلب خبرة واسعة مع أكثر من 500 نشرة مُراجعة من الأقران.
بصفته نائب مدير في مركز أورام الدماغ وحاصل على كرسي James B. Powell, Jr. المتميز، تأتي تعيين الدكتور فريدمان في وقت حاسم بينما تستعد NeOnc لنشر بيانات من برامجه السريرية NEO100™ و NEO212™. ستكون خبرته حاسمة في مراجعة وتوثيق هذه النتائج القادمة، لا سيما في مجالات الورم الأرومي الدبقي وأنواع أخرى من سرطانات الدماغ.
NeOnc Technologies (NTHI)，一家专注于中枢神经系统（CNS）癌症治疗的临床阶段生物制药公司，已任命Henry S. Friedman 博士进入其科学咨询委员会。Friedman 博士是来自杜克大学 Preston Robert Tisch 脑肿瘤中心的杰出神经肿瘤学家，带来丰富的经验，拥有超过500篇同行评审出版物。
作为 Brain Tumor Center 的副主任以及 James B. Powell, Jr. Distinguished Professorship 的持有人，Friedman 博士的任命在 NeOnc 准备公布其临床计划 NEO100™ 和 NEO212™ 的数据之际显得尤为关键。他的专业知识将在审查和验证这些即将公布的结果方面发挥重要作用，特别是在胶质母细胞瘤和其他脑部癌症领域。
- Appointment of internationally renowned neuro-oncologist Dr. Henry Friedman to scientific advisory board
- Strategic timing ahead of upcoming clinical data publication for NEO100 and NEO212 programs
- Addition of expert with over 500 peer-reviewed publications strengthens clinical development oversight
- None.
CALABASAS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. Henry S. Friedman to its scientific advisory board. Dr. Friedman is an internationally renowned academic adult and pediatric neuro-oncologist who helps to lead The Preston Robert Tisch Brain Tumor Center at Duke University. He is the author of more than 500 peer reviewed articles, reviews, and book chapters and has presented extensively at both international and national meetings.
“We are incredibly honored to welcome Dr. Henry Friedman, a true luminary in the field of neuro-oncology, to our scientific advisory board,” said Amir F. Heshmatpour, Executive Chairman and President of NeOnc Technologies. “His profound experience in developing novel therapies for CNS cancers and his distinguished career at Duke’s Preston Robert Tisch Brain Tumor Center will be invaluable as we advance our pipeline, including our lead candidates NEO100™ and NEO212™.
Mr. Heshmatpour added, “As NeOnc prepares to publish upcoming data from our NEO100 and NEO212 clinical programs, we look forward to our key opinion leaders carefully reviewing and validating these results. We believe their independent expertise will not only strengthen the confidence of our stakeholders but will also mark a turning point—one of destiny—for patients and families battling glioblastoma and other brain cancers. Together, with the guidance of leaders like Dr. Friedman, we are committed to changing the future for those who need it most.”
Henry S. Friedman, MD, Duke University
Henry S. Friedman is a senior neuro-oncologist at Duke and longtime leader at The Preston Robert Tisch Brain Tumor Center, where he serves as a deputy director and holds the James B. Powell, Jr. Distinguished Professorship in the School of Medicine. He cares for adult and pediatric patients at the Duke Cancer Center’s Brain Tumor Clinic and is an internationally renowned authority in neuro-oncology, with a publication record exceeding 500 peer-reviewed works and decades of national and international presentations. His work has spanned clinical trials and translational research across high-grade glioma, medulloblastoma, and ependymoma, helping to shape modern standards for difficult central nervous system (CNS) tumors. He has offered sustained leadership to one of the field’s best-known programs and ongoing engagement with collaborative, multi-center research efforts.
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonc.com.
Important Cautions Regarding Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information. Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.
The “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
info@neonc.com
Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
James@haydenir.com
FAQ
Who is Dr. Henry S. Friedman and why is his appointment significant for NeOnc Technologies (NTHI)?
What clinical programs is NeOnc Technologies (NTHI) currently developing?
What is NeOnc Technologies' (NTHI) current development stage?
What role will Dr. Friedman play in NeOnc Technologies' (NTHI) development programs?
